The Journal of Immunology, Vol 130, Issue 6 2623-2628, Copyright © 1983 by American Association of Immunologists

ARTICLES

Blocking of human T lymphocyte functions by anti-Leu-2 and anti-Leu-3 antibodies: differential inhibition of proliferation and suppression

EG Engleman, CJ Benike, C Metzler, PA Gatenby and RL Evans

We have shown previously that monoclonal antibodies to the Leu-2 and Leu-3 T cell antigens block the response of their respective subsets in allogeneic MLR. The present study was an effort to explore the mechanism of inhibition and to determine if anti-Leu-2 and anti-Leu-3 antibodies affect the responses to stimuli in addition to alloantigens. Our results indicate that antibodies to Leu-2 and Leu-3 have profound inhibitory effects on proliferation by their respective T cell subsets responding to a variety of stimuli, including specific soluble antigens and alloantigen. This effect was characterized by the following features: a) For optimal inhibition of proliferation, antibody must be present at the onset of antigenic stimulation. b) Inhibition is augmented by increasing the concentration of antibody or decreasing the concentration of antigen. c) Fab fragments of both anti-Leu-2a and anti- Leu-3a antibodies also block proliferation. In addition to their effects on T cell proliferation, anti-Leu-3 antibody blocked T cell- dependent lg synthesis induced in MLR, and anti-Leu-2 antibody prevented the induction, in vitro, of Leu-2+3- suppressor cells of lg synthesis. Taken together, these results suggest that antibodies to antigenic determinants on the Leu-2 and Leu-3 molecules competitively block segments of these structures that bind to alloantigen or nominal antigen. On the other hand, anti-Leu-2a antibody failed to block suppression of the MLR by in vivo activated, antigen-specific Leu-2+3- suppressor cells, which suggests that the Leu-2a epitope does not transmit antigen-specific signals from these differentiated suppressor T cells.

This article has been cited by other articles:

				J. D. Scandling, S. Busque, S. Dejbakhsh-Jones, C. Benike, M. T. Millan, J. A. Shizuru, R. T. Hoppe, R. Lowsky, E. G. Engleman, and S. Strober Tolerance and Chimerism after Renal and Hematopoietic-Cell Transplantation N. Engl. J. Med., January 24, 2008; 358(4): 362 - 368. [Abstract] [Full Text] [PDF]

				J. L. Rossio, M. T. Esser, K. Suryanarayana, D. K. Schneider, J. W. Bess Jr., G. M. Vasquez, T. A. Wiltrout, E. Chertova, M. K. Grimes, Q. Sattentau, et al. Inactivation of Human Immunodeficiency Virus Type 1 Infectivity with Preservation of Conformational and Functional Integrity of Virion Surface Proteins J. Virol., October 1, 1998; 72(10): 7992 - 8001. [Abstract] [Full Text] [PDF]

				J. Lifson, K. Hwang, P. Nara, B Fraser, M Padgett, N. Dunlop, and L. Eiden Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity Science, August 5, 1988; 241(4866): 712 - 716. [Abstract] [PDF]

				S. Putney, T. Matthews, W. Robey, D. Lynn, M Robert-Guroff, W. Mueller, A. Langlois, J Ghrayeb, S. Petteway Jr, K. Weinhold, et al. HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope Science, December 12, 1986; 234(4782): 1392 - 1395. [Abstract] [PDF]